Online news platform Tech Company News caught up with Asymmetrex Director James Sherley to ask him about his expectations for Asymmetrex’s new membership in ARMI.
“Working with our partner AlphaSTAR Corporation, Asymmetrex has solved the first problem. We now offer the first ever technology for specific and accurate counting of any human tissue stem cell type, including blood stem cells, liver stem cells, stem cells derived from fat, and others under evaluation for medical applications. This expertise and technology is what we bring to ARMI BioFabUSA with our new membership.”
AsymmetrexAsymmetrex Talks with Tech Company News About Introducing Tissue Stem Cell Counting to the Advanced Regenerative Manufacturing Institute (ARMI)
The information provided by Asymmetrex (“we”, “us”, or “our”) on the Stem Cell Counting Center
Portal [https://asymmetrex.com/stem-cell-counting-center/] (the “Portal”) however accessed,
by internet browser or mobile application, is for general informational purposes only.
All information on the Portal is provided in good faith, however we make no representation or
warranty of any kind, express or implied, regarding the accuracy, adequacy, validity,
reliability, availability or completeness of any information provided to you by the Portal.
In specific, the Portal cannot and does not contain medical or health advice, or treatment
recommendations. The information is provided for general informational and educational purposes
only and is not a substitute for the advice of a qualified medical professional. Accordingly,
before taking any actions based upon information from the Portal, such as formulating dosage
levels and/or treatment plans, we encourage you to consult with a qualified medical professional
and/or specialist. UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE
OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE PORTAL, OR RELAINCE ON ANY INFORMATION PROVIDED
BY THE PORTAL. YOU AGREE AND ARE AWARE YOUR USE OR RELIANCE OF ANY PORTAL INFORMATION IS SOLELY AT
YOUR OWN RISK.
Leave a Reply